Company Overview and News
About half the 94 units at Wings At Sea released by Sun Hung Kai Properties over the weekend have been snapped by those in the 22-37 age group
Hong Kong conglomerate New World Development is part of a consortium that has won the tender for a luxury residential site close to Orchard Road, Singapore’s famous shopping and entertainment strip, securing the plot for S$2,377 per square foot, a record for all government residential sites in the city.
Once touted as ‘Richard Li’s right-hand man’, does one of Hong Kong’s savviest deal makers have what it takes to found a new property empire to rival that of Henderson or New World?
Hong Kong tycoon Victor Li Tzar-kuoi sees political considerations as a major barrier to a government plan for joint public and private development of agricultural land for housing, casting doubt on whether the model could help boost home affordability in the city.
The group’s subsidiary Roxy will undertake the project set on 25 hectares of land and will complete it in phases between 2023 and 2027
Analysts say pop-up stores allow retailers and mall operators to gather customers’ response quickly and adjust their business plans to capture opportunities
Office rents in Tsim Sha Tsui could rise 6 per cent, says Colliers, as new supply, express rail link attract tech companies from the mainland
Hong Kong’s developers are shrinking their apartments, as surging prices severely limit the amount of money that first-time buyers and school-leavers can put down on their property, putting all but the smallest units beyond their budgets.
Henry Cheng Kar-shun, the chairman of Hong Kong’s New World Development, will release his £8.4 billion (US$11.97 billion) redevelopment project in East London to Hong Kong buyers on Friday, April 20.
Ping An Insurance (Group) (OTCPK:PIAIF) (OTCPK:PNGAY) plans to carve out its Ping An Healthcare and Technology (also known as Ping An Good Doctor APP) and IPO in Hong Kong for $1 billion at a valuation of $5 billion. The company plans to go public in the middle of May. In May 2016, Ping An Healthcare and Technology raised $500 million in a Series A. In December 2017, the company raised $400 million from Softbank Union in a pre-IPO round.
Close to 300 flats lie disturbingly vacant in a completed new residential development in Ho Man Tin even as the Hong Kong government struggles to resolve the perennial short supply of housing in the world’s most expensive property market.
China goes on vacation Thursday and Friday for the Qingming Festival, so the news may be a bit light over the rest of the week.
Chinese drug maker Hua Medicine, which is studying a potential stock market listing, raised US$117 million in a combined fourth and fifth round of funding to pay for clinical trials and the commercialisation of its diabetes drugs.
But company’s chairman says city is ‘new to the game’ and stakeholders will have plenty of ‘lessons to learn’
The appeal of Hang Lung’s Gala Place and Hollywood Plaza malls has been in decline amid a shifting retail landscape, says Knight Frank
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...